Long-term real-world protection afforded by third mRNA doses against symptomatic SARS-COV-2 infections, COVID-19-related emergency attendances and hospitalizations amongst older Singaporeans during an Omicron XBB wave.

Liang En Ian WeeDeanette PangCalvin ChiewJanice TanVernon LeeBenjamin OngDavid Chien LyeKelvin Bryan Tan

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)

Our results highlight the benefit of a booster dose in reducing ED attendances and hospitalizations amongst older adults aged ≥60 years with no documented prior SARS-CoV-2 infection, during an Omicron XBB wave; up to and beyond 360 days post-booster. A second booster provided further reduction.

Keyphrases

sars cov
respiratory syndrome coronavirus
emergency department
physical activity
coronavirus disease
public health
middle aged